Risperidone Dose Increase for Tics
Yes, you should increase the risperidone dose from 0.25 mg BID to 0.5 mg BID (total daily dose from 0.5 mg to 1 mg), as the current dose is subtherapeutic and the patient experienced initial benefit that has waned.
Rationale for Dose Increase
Your patient is on 0.25 mg twice daily (0.5 mg total daily), which is well below the therapeutic range for tic disorders. The FDA label for risperidone indicates that for irritability in autistic disorder (the closest FDA-approved pediatric indication), the initial target dose is 0.5-1 mg daily, with an effective range of 0.5-3 mg daily 1.
The fact that the patient experienced initial benefit ("I noticed a big difference" with reduced jerking and urges) but this effect diminished after a few days strongly suggests tolerance at a subtherapeutic dose rather than treatment failure. This is a classic pattern indicating the need for dose optimization.
Evidence-Based Dosing for Tics
Multiple studies support risperidone's efficacy for tic disorders at higher doses than your patient is currently receiving:
- Research evidence demonstrates that risperidone is effective for Tourette syndrome and chronic tic disorders at mean doses of 2.7 mg/day (range 0.5-9 mg/day) in adults 2
- In pediatric populations, effective doses ranged from 1-6 mg/day, with significant tic reduction (26-66%) observed 3
- A comparative trial showed risperidone superior to pimozide for tic suppression 4
- European guidelines (2022) support risperidone as a first-line pharmacological option for tic disorders 5
Recommended Titration Strategy
Increase to 0.5 mg BID (1 mg total daily) as the next step:
- This doubles the current dose but remains conservative and within safe limits
- Monitor for 2-3 weeks at this dose before considering further increases
- If inadequate response at 1 mg daily, can increase by 0.5 mg increments every 2-3 weeks
- Target therapeutic range: 1-3 mg daily for tic control in most patients
- Maximum studied doses in pediatric tic disorders: up to 6 mg daily 3, 4
Safety Monitoring
Watch for extrapyramidal symptoms (EPS), which become more common at doses ≥2 mg daily 6:
- Monitor for muscle stiffness, tremor, restlessness, or dystonia
- Weight gain is the most common side effect (expect 1-2 kg over 4 weeks) 4, 7
- Since mood and anxiety are stable, focus monitoring on movement side effects and weight
Important Caveats
- The initial "wearing off" after a few days suggests the 0.25 mg BID dose was insufficient to maintain therapeutic dopamine receptor occupancy
- Do not increase faster than every 2-3 weeks to allow assessment of true efficacy at each dose level
- If tics worsen significantly with dose increases, consider alternative agents (clonidine, guanfacine, aripiprazole) 8, 5
- The patient's upcoming job transition is a good motivator for optimizing treatment now
The evidence strongly supports that your patient is underdosed, and a careful upward titration is both safe and likely to restore the initial benefit they experienced.